Hemogenyx Pharmaceuticals PLC Announces Total Voting Rights

Arizona Tribune - Hemogenyx Pharmaceuticals PLC Announces Total Voting Rights

Hemogenyx Pharmaceuticals PLC Announces Total Voting Rights

LONDON, GB / ACCESS Newswire / March 31, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the total issued share capital of the Company as at 31 March 2025 consists of 4,093,539 ordinary shares of 1p each, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 4,093,539.

Text size:

The figure of 4,093,539 ordinary shares may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their investment in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Enquiries:

Hemogenyx Pharmaceuticals plc	https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder	[email protected]
Peter Redmond, Director	[email protected]
SP Angel Corporate Finance LLP	Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Adam Cowl
Peterhouse Capital Limited	Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.

The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

SOURCE: Hemogenyx Pharmaceuticals PLC

View the original press release on ACCESS Newswire

G.P.Martin--AT

CMSC	-0.53%	21.93	$
CMSD	-0.73%	21.77	$
BCC	1.56%	81.02	$
JRI	1.64%	12.79	$
BCE	-1.22%	22.92	$
RBGPF	5.69%	65	$
RIO	-1.46%	93.74	$
RYCEF	2.12%	18.39	$
NGG	-0.49%	83.01	$
VOD	0.22%	13.89	$
AZN	1.45%	188.41	$
GSK	1.16%	52.5	$
RELX	1.34%	31.34	$
BP	-1.59%	37.13	$
BTI	0.45%	62.76	$

Arizona Tribune - Hemogenyx Pharmaceuticals PLC Announces Total Voting Rights

Hemogenyx Pharmaceuticals PLC Announces Total Voting Rights

Featured

Venezuela quakes kill 1,400 as time running out to find survivors

A painful wait by a pile of rubble in quake-hit Venezuela

Solidarity, sadness among Venezuelans made destitute by quake

Aid planes landing at partially reopened Venezuela airport after quakes